Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.

Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers.  Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com.

Note: Olema will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview.  Though we use third party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Olema.

Olema Oncology

Welcome to our newest team members, Emma Curran and Liza Bakunina MD, MS! We're excited to have you join Olema, where we're dedicated to transforming the lives of women with cancer. Together, we're #OntoSomethingBigTogether.

Learn more about opportunities at Olema today: https://bit.ly/46oWjdm

Make a meaningful difference for women battling #cancer. Join us on our mission to transform the standard of care for women with cancer. Apply today: https://bit.ly/46oWjdm

#OntoSomethingBigTogether #ClinicalScience #BioTechJobs #CMC #ClinicalSupplyChain #WomensOncology #Oncology #ClinicalDevelopment

And the list goes on! Every day, we find inspiration in the impact of our work and the commitment to scientific advancements.

Make a difference with Olema. Apply today: https://bit.ly/46oWjdm #OntoSomethingBigTogether #Oncology #WomensOncology #Biotech

Today, we honor the legacy of Dr. Martin Luther King Jr., a beacon of hope, justice, and equality. Let us carry his legacy forward, standing united for a better tomorrow. #OntoSomethingBigTogether #MLKDay #MartinLutherKing #Equality

Please welcome our new Senior Medical Director, Elisabeth de Kermadec, MD, MPH! Elisabeth is very excited to join Olema to be able to focus on her professional interest in breast cancer and develop treatments that can improve the lives of patients living with breast cancer.

Elisabeth is a medical gynecologist specializing in #BreastCancer. Elisabeth obtained her medical degree from the Paris V Descartes University in France and her MPH degree from Paris Sud University, France. She did postdoctoral training at the Dana-Farber Cancer Institute in Boston, where she explored fertility issues in young women with breast cancer. #OntoSomethingBigTogether #BreastCancerResearch

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	116K -	935K 706.03%	719K 23.10%	23K 96.80%	374K 1,526.09%	2.70M 621.39%
accumulated other comprehensive income loss	-71K -		-342.72M -	-149K 99.96%	-1.81M 1,116.78%	347K 119.14%
cash and cash equivalents	3.15M -	68K 97.84%	338.55M 497,766.18%	287.25M 15.15%	23.70M 91.75%	68.54M 189.17%
cash and short term investments	3.15M -	68K 97.84%	338.55M 497,766.18%	287.25M 15.15%	204.42M 28.84%	261.81M 28.07%
common stock			3K -	3K 0%	3K 0%	4K 33.33%
deferred revenue				7.69M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory					-319K -
long term debt				2.36M -	1.55M 34.27%	1.43M 7.81%
long term investments						7.17M -
net debt	-3.15M -	-68K 97.84%	-338.55M 497,766.18%	-283.96M 16.12%	-21.14M 92.56%	-66.12M 212.83%
net receivables					319K -	673K 110.97%
other assets						1 -
other current assets	93K -	35K 62.37%	149K 325.71%	223K 49.66%	4.48M 1,908.07%	4.03M 9.94%
other current liabilities	85K -	443K 421.18%	3.87M 772.69%	378K 90.22%	15.16M 3,910.58%	17.93M 18.30%
other liabilities
other non current assets	3K -	3K 0%	510K 16,900%	3.98M 679.41%	2.77M 30.29%
other non current liabilities	9.35M -			-1K -
othertotal stockholders equity	239K -	168K 29.71%	371.23M 220,869.05%	388.90M 4.76%	408.33M 5.00%	559.18M 36.94%
preferred stock			342.72M -
property plant equipment net	26K -	26K 0%	75K 188.46%	4.72M 6,193.33%	3.98M 15.78%	3.26M 18.01%
retained earnings	-6.45M -	-10.76M 66.96%	-33.09M 207.51%	-104.19M 214.83%	-208.98M 100.57%	-305.63M 46.25%
short term debt				931K -	1.01M 9.02%	988K 2.66%
short term investments				273.44M -	180.72M 33.91%	193.27M 6.94%
tax assets
tax payables			642K -	88K 86.29%	67K 23.86%	73K 8.96%
total assets	3.27M -	132K 95.96%	342.72M 259,537.88%	295.94M 13.65%	215.65M 27.13%	276.94M 28.43%
total current assets	3.24M -	103K 96.82%	342.14M 332,071.84%	287.25M 16.04%	208.90M 27.28%	266.51M 27.58%
total current liabilities	201K -	1.38M 585.57%	4.58M 232.73%	9.02M 96.71%	16.55M 83.49%	21.62M 30.65%
total debt				3.29M -	2.56M 22.01%	2.42M 5.77%
total investments				273.44M -	180.72M 33.91%	200.44M 10.91%
total liabilities	9.55M -	10.73M 12.33%	4.58M 57.25%	11.38M 148.11%	18.10M 59.10%	23.05M 27.36%
total liabilities and stockholders equity	3.27M -	132K 95.96%	342.72M 259,537.88%	295.94M 13.65%	215.65M 27.13%	276.94M 28.43%
total non current assets	29K -	29K 0%	585K 1,917.24%	8.70M 1,386.32%	6.75M 22.42%	10.43M 54.64%
total non current liabilities	9.35M -	9.35M 0%		2.36M -	1.55M 34.24%	1.43M 7.81%
total stockholders equity	-6.28M -	-10.59M 68.75%	338.14M 3,291.78%	284.57M 15.84%	197.55M 30.58%	253.90M 28.52%

COM:OLEMA

Olema Pharmaceuticals Inc (Olema Oncology)

Last Close

12.72

12/11 21:00

Market Cap

649.39M

Beta: -

Volume Today

640.33K

Avg: -

Preview